Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Product/Service, Trade Show

Agilent Completes the InfinityLab Bio LC Portfolio


Agilent Technologies Inc. (NYSE: A) today announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release is central to the Agilent portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that seamlessly integrate with Agilent OpenLab and MassHunter software, and CrossLab services to maximize efficiency in biopharma labs.

The three new systems include the 1290 Infinity II Bio LC System with High-Speed Pump, the 1290 Infinity II Bio LC System with Flexible Pump, and the 1260 Infinity II Prime Bio LC System. These systems are based on the proven, award-winning InfinityLab LC technology and were designed to help future-proof laboratories by providing a universal LC platform that delivers InfinityLab LC reliability and performance with additional bio-analysis capability and even greater resistance to harsh analytical conditions.

"This is a significant portfolio release that further demonstrates Agilent's commitment to the fast-growing biopharma LC market," said Stefan Schuette, vice president, and general manager of Agilent's Liquid Phase Separations Division. "By offering new instruments, columns, application kits, and supplies we're providing solutions that customers can tailor to meet their specific bio-analytical requirements, including seamless transfer of existing methods from both Agilent and non-Agilent LC systems."

Agilent also announced the planned release of several new workflow solutions based on the Bio LC core systems. These specialized solutions include a new, biocompatible 2D-LC, method development, and a new Online LC solution for process monitoring and process analytical technology (PAT). These new solutions will complement already existing bio-analytical LC/Q-TOF MS, SEC (Size Exclusion Chromatography) and bio-purification solutions from Agilent.

The Bio LC portfolio launch takes center stage at the first InfinityLab LC Virtual Conference taking place on 22nd ? 23rd June 2021. For more information, visit the event registration page.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.


These press releases may also interest you

at 00:25
Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial...

28 mar 2024
The report titled "Central Lab Market by Service Type (Anatomic Pathology/Histology, Biomarker Services, Genetic Services), Phase (Phase 1, Phase 2, Phase 3), Therapeutic Area, End-use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Personalized Nutrition Market by Measurement Type (Active Measurement, Standard Measurement), Application (Indication-based, Standard Supplements), Distribution Channel, End-Use - Global Forecast 2024-2030" is now available on...

28 mar 2024
The report titled "Carbon Dioxide Incubator Market by Product (Air Jacketed CO2 Incubators, Direct Heat CO2 Incubators, Water Jacketed CO2 Incubators), Capacity (100-200 Litre, Above 200 Litre, Below 100 Litre), Application, End User - Global...

28 mar 2024
The "Global Clinical In Vitro Diagnostic Medical Laboratory Services Market: Strategy & Trends with Volume & Price Forecasts by Chemistry, Hematology, Microbiology, Pathology, Covid-19, and Molecular Dx by Country. Updated with Impact of COVID-19"...

28 mar 2024
The "Molecular Diagnostics at the Point of Care. By Application, Technology, Place, Product and by Country. With Executive Guides and Customization 2023 - 2027 " report has been added to  ResearchAndMarkets.com's offering. Infectious disease Dx is...



News published on and distributed by: